# Taixing Borui Biopharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/taixing-borui-biopharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Taixing, China
- Latest round: Series A (Mar 12, 2026)
- Investors on record: 1

## About

Based in Taixing, China, and founded in 2007, Borui Biopharmaceutical Taixing Co., Ltd., trading as Taixing Borui Biopharmaceutical, is an active pharmaceutical ingredient (API) manufacturer and R&D company dedicated to the production and research of APIs for innovative drugs. In March 2026, Taixing Borui Biopharmaceutical raised a series A funding from Fuzhe Capital.
The company’s business scope includes biological APIs (such as Neomocontin, Acarbose, Vancomycin, Epomycin, DAPTOmycin, S-adenosylmethionine, Ascaridin, Sirolimus, Fidamirin, Caspofungin, Micafungin, Anifungin, and Pimecrolimus).
The company’s revenue is generated by providing biological APIs drugs.

## Funding rounds

- Series A, Mar 12, 2026 — Fuzhe Capital

## Investors

- Fuzhe Capital (https://capitalatlas.ai/funds/fuzhe-capital) — Series A